The psychotic disorder treatment market is USD 13.6 billion in 2025. Fact.MR estimates the psychotic disorder treatment market to grow at a CAGR of 6.3% and will be USD 24.5 billion by 2035. The increasing incidence of schizophrenia, schizoaffective disorder, and delusional disorders is fueling demand for long-term therapeutic practices and better drug formulations. As a result of increasing awareness and early detection, demand for effective, cost-effective, and patient-compliant treatments has significantly increased.

Improvements in lower side effects, atypical antipsychotics and higher levels of patient compliance are driving the trend. Improvements through long-acting injectables and personalized medicines are reducing relapse episodes, optimizing continuity of care, and facilitating outcomes-based reimbursement. The medical community is increasingly looking to multi-modal therapeutic approaches that combine pharmacological and psychosocial interventions with e-mental health solutions.

Key Takeaways from Market Study

• Global psychotic disorder treatment market to reach US$ 24.5 billion by 2032.
• Atypical antipsychotics segment is projected to dominate due to its efficacy and widespread use.
• Market in Europe to record a 4.8% CAGR over the forecast period of 2022-2032, holding a 25.4% market share in 2022.
• Market in the U.S. forecast to reach a valuation of US$ 5.2 billion by 2032, driven by high prevalence of schizophrenia and bipolar disorder.
• Increasing prevalence of mental health disorders and growing awareness to fuel market growth

“Increasing investments in R&D for novel therapies, rising prevalence of psychotic disorders due to lifestyle changes, and growing awareness of mental health are key drivers propelling the psychotic disorder treatment market forward,” says a Fact.MR analyst

Winning Strategy

Key market players are focusing on developing innovative therapies, particularly atypical antipsychotics and long-acting injectables, to address severe psychotic disorders like schizophrenia and bipolar disorder. Companies are investing heavily in R&D to create safer and more effective treatments with fewer side effects. Strategic alliances and acquisitions are also common to expand product portfolios and penetrate emerging markets. For instance:

• In May 2023, the U.S. FDA approved risperidone (Uzedy), an extended-release injectable for schizophrenia, offering flexible dosing intervals and rapid therapeutic effects.
• In December 2020, Novartis International AG acquired Cadent Therapeutics, introducing two novel medications (CAD-9303 and CAD-1883) for psychotic disorders.

Industry News

• In June 2020, Otsuka Pharmaceutical introduced Abilify Maintena, a long-acting injectable for bipolar disorder, enhancing treatment adherence
• In November 2022, MedinCell and Teva Pharmaceutical resubmitted a New Drug Application to the FDA for a risperidone-based long-acting injectable for schizophrenia treatment.

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global psychotic disorder treatment market, presenting historical demand data (2017-2021) and forecast statistics for the period of 2022-2032. The study provides essential insights based on drug type (atypical antipsychotics, phenothiazine antipsychotics, thioxanthenes), indication (schizophrenia, bipolar disorder, delusional disorder, drug-induced psychosis), and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), across five major regions (North America, Europe, Asia Pacific, Latin America, and MEA).

Key Companies Profiled

• Eli Lilly and Company
• Johnson & Johnson
• AbbVie, Inc. (Allergan Plc)
• Alkermes PLC
• Otsuka Pharmaceutical Inc.
• AstraZeneca PLC
• Teva Pharmaceutical Industries Ltd.

 Explore More Related Studies Published by Fact.MR Research

The global surgical equipment market stands at US$ 16.7 billion in 2023 and is forecasted to expand at an impressive 8.6% CAGR over the next ten years to reach US$ 38.1 billion in revenue by 2033-end.

The global automotive smart display market is expected to reach USD 18.2 billion by 2035, up from USD 8.2 billion in 2024. During the forecast period, the industry is projected to grow at a CAGR of 7.8%. Rising demand

The global polymerase chain reaction market size is expected to attain a valuation of US$ 6.2 billion in 2024. Projected to expand at a CAGR of 10%, worldwide sales of polymerase chain reaction products are foreseen to reach US$ 16 billion by 2034.

The global Isoprenol Market was valued at USD 337.7 million in 2024 and expand at a CAGR of 6.5% to end up at USD 675.0 million by 2035.

Global consumption of metallocene polyolefin is set to reach US$ 13.77 billion in 2022, and the market is expected to expand rapidly at a high CAGR of 9.5% to reach a market valuation of US$ 34.16 billion by the end of 2032.

The global steel pipe coatings market is estimated to be valued at US$ 8.8 billion in 2023 and it is expected to grow at a CAGR of 4.7% to reach US$ 14.0 billion by the end of 2033.

About Fact.MR

We are a trusted research partner of 80% of Fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.

Contact
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog